💊 दवाएँ A-Z 🧬 लक्ष्य 🛠 उपकरण 📚 मार्गदर्शिकाएँ
सभी दवाएँ दवा वर्ग चिकित्सीय क्षेत्र दुष्प्रभाव
मार्गदर्शिकाएँ शब्दकोश समयरेखा
तुलनाएँ दवाओं की यात्राएँ दवा परिवार
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Roflumilast

CHEMBL193240 Phase 4 अनुमोदित Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
403.2 g/mol
LogP
4.6
Phase
4

A phosphodiesterase-4 inhibitor used to reduce the frequency of flare-ups in severe chronic obstructive pulmonary disease by decreasing airway inflammation. It is taken as a daily oral tablet and is intended as an add-on therapy for patients with frequent COPD exacerbations.

आणविक भार

403.2000 g/mol

LogP

4.60

TPSA

60.50 Ų

लिपिंस्की RO5

उत्तीर्ण

चिकित्सीय क्षेत्र

अल्ज़ाइमर रोग अस्थमा एटोपिक डर्मेटाइटिस (एक्जिमा) क्रॉनिक ऑब्सट्रक्टिव पल्मोनरी डिज़ीज़ (COPD) टाइप 2 मधुमेह मेजर डिप्रेसिव डिसऑर्डर मोटापा लिम्फोमा ल्यूकेमिया सिज़ोफ्रेनिया सोरायसिस हृदय विफलता हृदय-संवहनी रोग

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D संरचना

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
O=C(Nc1c(Cl)cncc1Cl)c1ccc(OC(F)F)c(OCC2CC2)c1

                

                

                
                

                    
InChI

                    
InChI=1S/C17H14Cl2F2N2O3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17H,1-2,8H2,(H,22,23,24)

                

                

                

                    
                    

                        
Molecular Formula

                        
C17H14Cl2F2N2O3

                    

                    
                    

                        
HBD / HBA

                        
1 / 6

                    

                    
                    

                        
घूर्णनीय बंधन

                        
7

                    

                    
                    
                    

                        
भारी परमाणु

                        
26

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
अक्सर पूछे जाने वाले प्रश्न

                

                    
                    

                        
                        

                            
A phosphodiesterase-4 inhibitor used to reduce the frequency of flare-ups in severe chronic obstructive pulmonary disease by decreasing airway inflammation. It is taken as a daily oral tablet and is intended as an add-on therapy for patients with frequent COPD exacerbations.

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Roflumilast is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL193240.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 449193.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
चिकित्सा अस्वीकरण

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.